How do drugs work (Proceedings)
Aug 01, 2010
CVC IN KANSAS CITY PROCEEDINGS
The science of how drugs work on the body (or the microorganism or parasite) is pharmacodymanics (its counterpart being pharmacokinetics, how the body works on the drug). In this section, the basic concepts of drug concentration and drug action are followed by a review of the mechanisms of action of the major drug groups used in food animal practice including NSAIDs, glucocorticoids, reproductive drugs, antimicrobials, and parasiticides.
While this graph is a useful way to gauge response to different doses, it does not tell us what is causing the drug response. Drugs cause a response in the animal or the parasite in a number of ways, with the classical way being the receptor-mediated response. Other ways drugs can act include effects on enzymes (inhibiting or activating), effects on ion channels in cell walls (some of which are also "receptors" of some sort), and other non-specific actions (such as drugs that merely replace endogenous compounds or drugs that change osmolarity).Drugs Acting on Animal Cells
Mechanisms of Autonomic Drugs
Drugs commonly used in food animals that act through receptors include many of the autonomic drugs, such as xylazine (an alpha-2 agonist) and epinephrine. When these types of drugs interact with the receptor, a cascade of events is generally activated in the cell, resulting eventually in the desired pharmacological action (such as the sedation associated with xylazine, or the reversal of sedation associated with tolazoline). Xylazine and other alpha-2 agonists act by interacting with alpha-2 receptors on post-synaptic membranes, which are associated with inhibition of neurotransmission. Epinephrine acts on pre-synaptic alpha and beta receptors non-specifically, and causes among other things vasoconstriction and tachycardia.
Mechanism of Ion Channel Blockers
Drugs commonly used in food animals that act on ion channels include lidocaine. Lidocaine is the major example of an ion-channel active drug used in food animals. Lidocaine blocks voltage-gated sodium ion channels in nerves and therefore blocks nerve impulses. In general, blockade appears to affect, in order from first to last, pain, warmth, touch, deep pressure, and motor function, although this can be altered in nerve trunks in which for example motor nerves are more peripheral and therefore more likely to be affected by locally infiltrated lidocaine.
Mechanisms of NSAIDs
Drugs commonly used in food animals that act by inhibiting enzymes include NSAIDS. Omeprazole is another example of a drug that inhibits an enzyme, although it is not commonly used in food animals. NSAIDs work by inhibiting the cyclooxygenase enzymes, including its isoforms COX-1 and COX-2. Arachidonic acid released from plasma membranes is the substrate for these enzymes, and the end-product is a number of prostaglandins and prostacyclins, depending on the substrate available in the cell. Prostaglandins are often produced in excess during inflammation and are also associated with fever. Therefore, the reduction of prostaglandins may result in decreased inflammation and fever. Prostaglandins are also associated with pain, and reduction in prostaglandin production can reduce the central integration of nociception known as pain.
Common discussions in the literature now include the appreciated of the differences in affinity of NSAIDs for COX-1 and COX-2 isoforms of the enzyme. COX-1 is generally thought to be expressed constitutively, meaning essentially all the time, and is associated with protective functions, such as regulation of kidney afferent blood flow and mucus production in the gastric and duodenal mucosa. COX-2 is generally thought to be expressed particularly under conditions of inflammation, and therefore, it has been believed that inhibition of COX-2 preferentially would provide a margin of safety. This has been shown to be true in some cases for some drugs, but not always. Allegedly COX-2 selective drugs have been associated with gastric perforation. Part of the issue is how drugs are designated COX-1 vs. COX-2 selective, since the assays to determine the inhibitory ratio for the two isoforms are generally performed in vitro, and the assay used has been shown to alter the ratio significantly. In addition, there are species differences in the specificity for enzyme isoform, so extrapolation from other species is not always accurate.
There appear to be no published data on plasma concentrations associated with efficacy, or pharmacokinetic parameters associated with efficacy.